Loading stock data…
$15.04+0.26 (+1.76%)
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Erasca, Inc. in the Healthcare sector is trading at $15.04 with a market capitalization of $5.3B. Wall Street consensus targets $24.11 (9 analysts), implying a +60.3% move over the next 12 months. The stock is currently 38% below its 52-week high of $24.28, remaining 4.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$47.62M↓ | -$37.91M↓ | -$32.60M↓ | -$32.55M↓ | -$30.63M |
| Net Income | -$44.08M↑ | -$183.44M↓ | -$29.09M↑ | -$30.61M↑ | -$33.88M |
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glu...